Levi & Korsinsky has launched an investigation into Boston Scientific Corporation (BSX) for potential federal securities law violations. This comes after the company’s electrophysiology segment’s Q4 2025 sales significantly missed analyst expectations, despite overall earnings and revenue exceeding estimates. The announcement led to a 17.5% drop in BSX shares, hitting a 52-week low.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Levi & Korsinsky Investigates Possible Securities Fraud by Boston Scientific Corporation (BSX)
Levi & Korsinsky has launched an investigation into Boston Scientific Corporation (BSX) for potential federal securities law violations. This comes after the company’s electrophysiology segment’s Q4 2025 sales significantly missed analyst expectations, despite overall earnings and revenue exceeding estimates. The announcement led to a 17.5% drop in BSX shares, hitting a 52-week low.